Vyome's VT-1953 Shows Significant Efficacy in Phase 2 Trial for Malignant Fungating Wounds — Vyome Holdings, Inc. (Vyome Therapeutics)

Event summary

Vyome presented Phase 2 data for VT-1953 at AACR 2026, showing significant reduction in malodor and pain for MFW patients.
VT-1953 improved median malodor scores from 0.5 to 4 on a 0-5 scale by Day 14 (P=0.0020), with no improvement in the control arm.
70% of patients reported improved quality of life with VT-1953 treatment (P=0.0256).
No treatment-associated adverse effects were reported.

The big picture

Vyome's Phase 2 data for VT-1953 addresses a critical unmet need in advanced cancer patients with Malignant Fungating Wounds, a condition affecting ~65K patients annually in the U.S. The positive results position VT-1953 as a potential first-in-class treatment, with significant implications for patient quality of life. The $2.2B market opportunity underscores the strategic importance of this development in the biopharmaceutical sector.

What we're watching

Regulatory Pathway: How quickly Vyome advances VT-1953 into registrational studies and secures FDA approval.
Market Potential: Whether the $2.2B U.S. MFW market estimate holds and how Vyome captures market share.
Execution Risk: The pace at which Vyome can leverage its US-India innovation corridor to advance other clinical-stage assets.